Want access to unlimited case records and advanced research tools? Create your free CasePortal account now. No credit card required to register.
Try CasePortal for FreeJ. Bibas dismisses patent infringement claims over a generic doxycycline treatment for rosacea by finding that the generic drug has a 22-mg immediate release portion and an 18-mg delayed release portion, not the 30/10 ratio contained in the premium drug.
To read this case, start your 14-day free trial.
Request a free trial account to get access to more case data, documents, and features.
To provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site and show (non-) personalized ads. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.